We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+8.13%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$988M
AUM Growth
-$31.3M
Cap. Flow
-$56.5M
Cap. Flow %
-5.72%
Top 10 Hldgs %
45.25%
Holding
164
New
47
Increased
25
Reduced
25
Closed
38

Top Buys

Rank Stock Value
1
OTIC
Otonomy, Inc.
OTIC
+$16.6M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$11.4M
3
ARWR icon
Arrowhead Research
ARWR
+$11.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.4M
5
EPZM
Epizyme, Inc
EPZM
+$7.5M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$37M
2
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$24.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.9M
4
SHPG
Shire pic
SHPG
+$21.2M
5
INSM icon
Insmed
INSM
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 79.83%
2 Financials 0.18%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$73.4M 7.43%
12,339,444
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.2B
$71.5M 7.24%
4,565,267
-34,600
-0.8% -$517K
AFMD
3
DELISTED
Affimed
AFMD
$63M 6.38%
+99,999
New +$6.24M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.64B
$54.8M 5.55%
2,596,691
+38,213
+1% +$862K
TLPH icon
5
Talphera
TLPH
$68M
$36.1M 3.65%
328,703
– –
CELG
6
DELISTED
Celgene Corp
CELG
$35.8M 3.62%
377,448
-130,040
-26% -$11.7M
PTCT icon
7
PTC Therapeutics
PTCT
$6.18B
$29.6M 2.99%
671,736
– –
DYAX
8
DELISTED
DYAX CORPORATION
DYAX
$28.7M 2.9%
2,835,498
+124,900
+5% +$1.21M
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.51B
$27.2M 2.75%
1,097,914
+444,914
+68% +$10.4M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$123B
$27M 2.73%
240,142
-230,000
-49% -$21.9M
SRPT icon
11
CALL
Sarepta Therapeutics
SRPT
$1.64B
$26.4M 2.67%
+1,250,000
New +$28.2M
ZBH icon
12
Zimmer Biomet
ZBH
$18.8B
$25.4M 2.57%
260,075
+10,300
+4% +$1.01M
TARO
13
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$21.7M 2.19%
140,935
-160,398
-53% -$24.1M
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$20.3M 2.05%
520,165
+148,696
+40% +$5.84M
OTIC
15
DELISTED
Otonomy, Inc.
OTIC
$20.1M 2.03%
+837,400
New +$16.6M
RCPT
16
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$19.5M 1.97%
313,594
+108,594
+53% +$5.19M
TSRO
17
DELISTED
TESARO, Inc.
TSRO
$19.1M 1.93%
708,284
+71,328
+11% +$2.1M
ARWR icon
18
Arrowhead Research
ARWR
$12.1B
$18.4M 1.87%
1,247,495
+825,089
+195% +$11.3M
XNCR icon
19
Xencor
XNCR
$1.45B
$17.9M 1.81%
1,922,707
+182,086
+10% +$1.84M
HCA icon
20
HCA Healthcare
HCA
$90.6B
$16.2M 1.64%
230,306
+32,500
+16% +$2.15M
RLYP
21
DELISTED
RELYPSA INC COM
RLYP
$16.1M 1.63%
762,705
+166,100
+28% +$4.03M
XLRN
22
DELISTED
Acceleron Pharma
XLRN
$13.5M 1.36%
445,000
+145,000
+48% +$4.08M
TVTX icon
23
Travere Therapeutics
TVTX
$5.17B
$12.4M 1.26%
1,379,137
+104,845
+8% +$1.23M
AEGR
24
DELISTED
Aegerion Pharmaceuticals
AEGR
$12.2M 1.24%
+366,754
New +$11.4M
NBIX icon
25
PUT
Neurocrine Biosciences
NBIX
$18.2B
$10.2M 1.04%
+653,000
New +$9.76M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Perceptive Advisors held 164 positions worth $988M, down 3.1% from $1.02B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $56.5M in Q3 2014, closing 38 positions and reducing 25 holdings. Its most notable exit was QUESTCOR PHARMA INC, an estimated $37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Otonomy, Inc. worth $20.1M.

  • Perceptive Advisors's largest Q3 2014 buy was Otonomy, Inc.: 837,400 shares worth $20.1M.
  • Perceptive Advisors added most to Arrowhead Research in Q3 2014, an estimated $11.3M increase.
  • Perceptive Advisors's biggest Q3 2014 reduction was Taro Pharmaceutical Industries Ltd., cutting an estimated $24.1M.
  • Perceptive Advisors fully exited QUESTCOR PHARMA INC in Q3 2014, selling an estimated $37M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $988M portfolio in Q3 2014.
  • Perceptive Advisors opened 47 new positions and closed 38 in Q3 2014.
  • Perceptive Advisors's portfolio value fell 3.1% quarter-over-quarter to $988M.

Based on Perceptive Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.